Galecto
Ole Maaloes Vej 3, Copenhagen, Capital Region of Denmark, 2200, Denmark
Overview
Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medical need. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 8
Sector focus
- Biotechnology
- Health Care
- Health Diagnostics
Investment portfolio
- Galecto
Participated · Equity · Sep 2020
Galecto is a clinical-stage biopharma focused on creating first-in-class treatments for cancer and liver diseases. Through its acquisition of Damora Therapeutics, Galecto has added a portfolio of antibody therapies that target mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms (MPNs) such as Essential Thrombocythemia and Myelofibrosis. The lead asset, DMR-001, is a potentially best-in-class anti-mutCALR monoclonal antibody engineered for subcutaneous dosing and is expected to file an IND in mid-2026, with Phase 1 proof-of-concept data anticipated in 2027. Two additional antibodies, DMR-002 and DMR-003, are slated to enter Phase 1 studies thereafter. Galecto’s legacy pipeline also includes GB3226, a dual ENL-YEATS and FLT3 inhibitor being advanced toward an IND submission in Q1 2026 for acute myeloid leukemia. Following the $284.9 million private placement completed alongside the Damora acquisition, management projects a cash runway into 2029, sufficient to reach multiple clinical readouts. After conversion of the new preferred shares, Galecto will have 61,998,882 common shares outstanding.